252 related articles for article (PubMed ID: 30542054)
1. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
[TBL] [Abstract][Full Text] [Related]
2. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.
Herlemann A; Huang HC; Alam R; Tosoian JJ; Kim HL; Klein EA; Simko JP; Chan JM; Lane BR; Davis JW; Davicioni E; Feng FY; McCue P; Kim H; Den RB; Bismar TA; Carroll PR; Cooperberg MR
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):136-143. PubMed ID: 31455846
[TBL] [Abstract][Full Text] [Related]
3. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
4. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
5. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
6. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
7. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
8. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
9. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
12. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
13. Identifying intermediate-risk candidates for active surveillance of prostate cancer.
Savdie R; Aning J; So AI; Black PC; Gleave ME; Goldenberg SL
Urol Oncol; 2017 Oct; 35(10):605.e1-605.e8. PubMed ID: 28736249
[TBL] [Abstract][Full Text] [Related]
14. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245
[TBL] [Abstract][Full Text] [Related]
15. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.
Murphy AB; Carbunaru S; Nettey OS; Gornbein C; Dixon MA; Macias V; Sharifi R; Kittles RA; Yang X; Kajdacsy-Balla A; Gann P
Urology; 2020 Aug; 142():166-173. PubMed ID: 32277993
[TBL] [Abstract][Full Text] [Related]
16. A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI.
Li L; Shiradkar R; Leo P; Algohary A; Fu P; Tirumani SH; Mahran A; Buzzy C; Obmann VC; Mansoori B; El-Fahmawi A; Shahait M; Tewari A; Magi-Galluzzi C; Lee D; Lal P; Ponsky L; Klein E; Purysko AS; Madabhushi A
EBioMedicine; 2021 Jan; 63():103163. PubMed ID: 33321450
[TBL] [Abstract][Full Text] [Related]
17. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
18. Use of the Decipher genomic classifier among men with prostate cancer in the United States.
Zaorsky NG; Proudfoot JA; Jia AY; Zuhour R; Vince R; Liu Y; Zhao X; Hu J; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gershman S; Cheng I; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura M; Schwartz SM; Ward KC; Wiggins C; Wu XC; Shoag JE; Ponsky L; Dal Pra A; Schaeffer EM; Ross AE; Sun Y; Davicioni E; Petkov V; Spratt DE
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37525535
[TBL] [Abstract][Full Text] [Related]
19. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
20. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
